IsoPlexis — Merger or Acquisition (December 2022)
17 slides from IsoPlexis's merger presentation, Dec 21, 2022
Slide 1: Berkeley Lights to Acquire IsoPlexis
Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a
Slide 3: Presenters
3 Presenters Siddhartha Kadia, Ph.D. CEO, BERKELEY LIGHTS Sean Mackay CEO, ISOPLEXIS Mehul Joshi CFO, BERKELEY LIGHTS
Slide 4: A Transformational Combination
A Transformational Combination Most comprehensive technology portfolio to isolate, manipulate, and characterize live cells (Nasdaq: CELL) A FUNCTIONAL CELL BIOLOGY COMPANY LIVE CELL, FUNCTIONAL BIOLOGY DEEP PROFILING OF SINGLE CELLS The only single-cell platform enabling functional proteomics+ 4 New
Slide 5: PhenomeX: The Functional Cell Biology Company
PhenomeX: The Functional Cell Biology Company WHAT WE DO Enable scientists to unlock the potential of cell biology for research and clinical applications HOW WE DO IT By providing a deeper analysis of cell function while preserving the live cells of interest WHY IT MATTERS Because understanding the
Slide 6: Transaction Summary
Transaction Summary 6 • All-stock transaction valued at $57.8 million • ISO shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold • BLI shareholders will own approximately 75.2% and ISO shareholders will own approximately 24.8% of PhenomeX • Siddhartha Ka
Slide 7: IsoPlexis at a Glance
IsoPlexis at a Glance 7 Highly Multiplexed Proteomic Barcoding 2. Single-cell capture 3. Highly multiplexed proteomic detection 1. Sample loaded onto chip 30+ Proteins Per Cell Rapidly Growing Installed Base Installed Base (Total Instruments) 209 234 254 277 Q4 Q1 Q2 Q3 ‘21 ‘22 Accelerating the figh
Slide 8: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan
Accelerates Progress Across Every Pillar of Berkeley Lights’ Strategic Plan 8 Building a world-class team Prioritizing R&D re turn on inves tment Delivering cons is tent commercia l execution Led by Berkeley Lights’ experienced Board of Directors Enhances a proven management team highly experienced
Slide 9: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan (continued)
9 Participating in a larger cell biology market with a wide range of tools and services through cross-selling opportunities to existing and new customers Enabling significant productivity through combined R&D, G&A and supply chain / manufacturing infrastructure Evaluating M&A opportunities that will
Slide 10: IsoPlexis Addresses Key Elements of Berkeley Lights' M&A Framework
IsoPlexis Addresses Key Elements of Berkeley Lights’ M&A Framework 10 Accelerate Profitable Growth Leverage Current Cost Structure Synergistic M&A options that expand total addressable market Complementary technology tuck-ins that expands BLI offerings Expansion of service offerings to existing and
Slide 11: PhenomeX: Investment Highlights
PhenomeX: Investment Highlights 11 Expanded and ba lanced product portfolio a t diffe rent price points with a focus on recurring revenue Pla tform for furthe r consolida t ion in high-growth, s ingle -ce ll biology tools space Substant ia lly expanded access to la rge r ce ll biology marke t , enha
Slide 12: Accelerated Development Path for Expanded and Balanced Product Portfolio
• Combina t ion with ISO facilita tes entry into high-growth academic resea rch segments • Crea tes ba lanced product portfolio − Lower ASP solutions affiliated with a variety of different customer segments − Unlocks various new applications • Expanding ins ta lled ba se − Provides ability to furthe
Slide 13: Significantly Expanded Overall Customer Base
Significantly Expanded Overall Customer Base Meaningfully expands breadth of BLI’s customer base and cross-selling opportunities while enhancing relationship with key overlapping accounts 13 Berkeley Lights Customers IsoPlexis Customers Overlapping commercia l channe ls and s ignificant cus tomer co
Slide 14: Cost Synergies Will Increase Profitability and Accelerate Timeline to Breakeven
Cost Synergies Will Increase Profitability and Accelerate Timeline to Breakeven 14 ~$70M cost synergies annualized by 2024 ~$150M in revenue, generating positive operating cash flow by 2024 Genera l and Adminis tra tive Cos t Synergies Marketing Resources and Sa les Opera tions Complementary R&D Cap
Slide 15: Investment Highlights
Investment Highlights 15 Expanded and ba lanced product portfolio a t diffe rent price points with a focus on recurring revenue Pla tform for furthe r consolida t ion in high-growth, s ingle -ce ll biology tools space Substant ia lly expanded access to la rge r ce ll biology marke t , enhanced comme
Slide 16: A Functional Cell Biology Company
A FUNCTIONAL CELL BIOLOGY COMPANY
Slide 17: Q&A Session
G BERKELEY LIGHTS 08 isoplexis Q&A Session